Impact of disease location on fecal calprotectin levels in Crohn's disease

Scandinavian Journal of Gastroenterology

Volumn 50, Issue 7, 2015, Pages 841-847

  Gecse, Krisztina B ^a,b   Brandse, Johannan F ^a   Van Wilpe, Sandra ^a   Löwenberg, Mark ^a   Ponsioen, Cyriel ^a   Van Den Brink, Gijs ^a   D'Haens, Geert ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Biomarker; Crohn's disease; CRP; Endoscopy; Fecal calprotectin; SES CD

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN;

ADOLESCENT; ADULT; ARTICLE; COLON ULCER; COLONOSCOPY; CORRELATIONAL STUDY; CROHN DISEASE; ELECTRONIC MEDICAL RECORD; FECES LEVEL; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; AGED; CHEMISTRY; COLON; COLONIC DISEASES; COMPARATIVE STUDY; COMPLICATION; FECES; ILEUM; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS; C-REACTIVE PROTEIN; COLON; COLONIC DISEASES; COLONOSCOPY; CROHN DISEASE; FECES; FEMALE; HUMANS; ILEUM; LEUKOCYTE COUNT; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84929148347     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2015.1008035     Document Type: Article

References (24)

1. D'Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2218-24.
2. Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 2014;63:88-95.
3. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010;105:162-9.
4. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008;103:162-9.
5. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006;55: 426-31.
6. TibbleJ,TeahonK,Thjodleifsson B,RosethA,SigthorssonG, Bridger S, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000;47:506-13.
7. Daperno M, D'Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004;60:505-12.
8. Rey JF, Lambert R, Committee EQA. ESGE recommendations for quality control in gastrointestinal endoscopy: guidelines for image documentation in upper and lower GI endoscopy. Endoscopy 2001;33:901-3.
9. Jensen MD, Kjeldsen J, Nathan T. Fecal calprotectin is equally sensitive in Crohn's disease affecting the small bowel and colon. Scand J Gastroenterol 2011;46:694-700.
10. Jones J, Loftus EV Jr, Panaccione R, Chen LS, Peterson S, McConnell J, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008;6:1218-24.
11. af Björkesten CG, Nieminen U, Turunen U, Arkkila P, Sipponen T, Farkkila M. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol 2012;47:528-37.
12. Sipponen T, Karkkainen P, Savilahti E, Kolho KL, Nuutinen H, Turunen U, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008;28:1221-9.
13. Parisinos CA, McIntyre VE, Heron T, Subedi D, Arnott ID, Mowat C, et al. Magnetic resonance follow-through imaging for evaluation of disease activity in ileal Crohn's disease: an observational, retrospective cohort study. Inflamm Bowel Dis 2010;16:1219-26.
14. Sipponen T, Haapamaki J, Savilahti E, Alfthan H, Hamalainen E, Rautiainen H, et al. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy. Scand J Gastroenterol 2012;47:778-84.
15. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22.
16. Papamichael K, Karatzas P, Mantzaris GJ. Faecal calprotectin but not C-reactive protein (CRP) or Crohn's Disease Activity Index (CDAI) may predict post-operative endoscopic recurrence of Crohn's disease. J Crohns Colitis 2013;7:e700-1.
17. Sipponen T, Bjorkesten CG, Farkkila M, Nuutinen H, Savilahti E, Kolho KL. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol 2010;45: 325-31.
18. Lobaton T, Lopez-Garcia A, Rodriguez-Moranta F, Ruiz A, Rodriguez L, Guardiola J. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. J Crohns Colitis 2013;7: e641-51.
19. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14:40-6.
20. Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142:63-70.e5; quiz e31.
21. Whitehead SJ, French J, Brookes MJ, Ford C, Gama R. Between-assay variability of faecal calprotectin enzymelinked immunosorbent assay kits. Ann Clin Biochem 2013;50:53-61.
22. Labaere D, Smismans A, Van Olmen A, Christiaens P, D'Haens G, Moons V, et al. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. United European Gastroenterol J 2014;2:30-7.
23. Lasson A, Stotzer PO, Ohman L, Isaksson S, Sapnara M, Strid H. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis 2015;9:26-32.
24. De Vos M, Louis EJ, Jahnsen J, Vandervoort JG, Noman M, Dewit O, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis 2013; 19:2111-17.